| 【Company Research】AAC Technologies (2018 HK) – Not out of the woods yet; more downside to 2022 earnings |
| 【Fixed Income Research】XIAOMI - Solid FY2021 result, tempered by its high spending appetite |
| 【Company Research】ZTE (763 HK) – Overhang removed; Focus on core business development |
| 【Company Research】Ever Sunshine (1995 HK) – Downgrade to Hold on margin and community VAS outlook |
| 【Fixed Income Research】YLLGSP - Initiating coverage with buy recommendations on YLLGSPs |
| 【Company Research】WuXi Biologics (2269 HK) – Growth momentum intact |
| 【Company Research】Tencent (700 HK) – Looking into 2H22E recovery |
| 【Company Research】InnoCare Pharma (9969 HK) – A successful commercial year for orelabrutinib |
| 【Company Research】Sunny Optical (2382 HK) – Headwinds to persist into 1H22E; Maintain HOLD |
| 【Company Research】Tongcheng-Elong (780 HK) – Looking beyond 3M22E epidemic |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
